Results of Operations and Financial Condition. On August 12, 2026, RenovoRx, Inc. issued a press release announcing its financial results as of and for the quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On August 12, 2026, RenovoRx, Inc. issued a press release announcing its financial results as of and for the quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock (the “Common Stock”) had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Mini…

Results of Operations and Financial Condition. On May 14, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended March 31, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On March 30, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the fiscal year ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Executive Chairman, Chief Medical Officer — Ramtin Agah, M.D.: Dr. Ramtin Agah was promoted to the newly created position of Executive Chairman while retaining his role as Chief Medical Officer.

Unregistered Sales of Equity Securities. To the extent required by

Entry into a Material Definitive Agreement. On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) in connection with a private placement offering by the Company (the “Offering”) to 15 accredited investors or qualified institutional buyers (the “Investors”), five of whom are directors, officers or employees of the Company (the “Insiders”) and the remaining are non-affiliated institutional in…

Principal Accounting Officer — Ronald B. Kocak: Mr. Kocak resigned from his position as Principal Accounting Officer, but retained his role as Vice President and Controller.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share (the “Common Stock”), failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based up…

Entry into a Material Definitive Agreement. On November 14, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”), and JonesTrading Institutional Services LLC (the “Agent”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”), pursuant to which the Company may issue and sell, from time to time, up to $3,723,029 in aggregate principal amount of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, through or to the Agent, as the Company’s…

Results of Operations and Financial Condition. On November 13, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On August 14, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On May 15, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Results of Operations and Financial Condition. On April 1, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Entry into a Material Definitive Agreement. On February 6, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) by and between the Company and Titan Partners Group LLC, a division of American Capital Partners, LLC, as the sole bookrunner (the “Underwriter”). Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter, in a firm commitment underwritten public offering (the “Offering”), 11,5…

and Item 9.01 (including Exhibit 99.1) of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Change in Registrant’s Certifying Accountant As previously reported on May 3, 2024, on April 29, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of RenovoRx, Inc. (the “Company”) received a letter from Baker Tilly US, LLP (“BT”), notifying the Committee that BT had decided to resign as the independent registered public accounting firm of the Company effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June…

Vice President, Controller and Principal Accounting Officer — Ronald B. Kocak: The company entered into a Change in Control and Severance Agreement with Ronald B. Kocak.

Change in Registrant’s Certifying Accountant On April 29, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of RenovoRx, Inc. (the “Company”) received a letter from Baker Tilly US, LLP (“BT”), notifying the Committee that BT has decided to resign as the independent registered public accounting firm of the Company effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which is expected to be filed…

The company approved salary increases and one-time cash bonuses for named executive officers following cost-cutting measures.

Other Events. As previously disclosed, on February 21, 2024, RenovoRx, Inc. (the “Company”) was notified by the Listing Qualifications Staff (the “Staff) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s securities were subject to delisting due to the Company’s non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million (the “Equity Requirement”) for continued listing on The Nasdaq Capital Market. The Company subsequently request…

Unregistered Sales of Equity Securities. To the extent required by

Other Events. On April 11, 2024, the Company, closed a previously announced private placement offering (the “Offering”) of an aggregate of (i) 6,960,864 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) a pre-funded warrant, in the form filed as Exhibit 10.2 to this Current Report (the “Pre-Funded Warrant”), with unlimited term, exercisable for a total of 951,500 shares of Common Stock, at an exercise price of $0.0001 per share (the…

Entry into a Material Definitive Agreement On April 4, 2024, RenovoRx, Inc. (the “Company”) entered into a series of definitive subscription agreements (the “Subscription Agreements”) in connection with a private placement offering by the Company (the “Offering”) to approximately 170 accredited investors (the “Investors”). The Offering is expected to close on April 11, 2024, subject to customary closing conditions. Under the provisions of the Subscription Agreements, in connection with the Of…